HomeProductsBioactive CompoundsCell CycleDNA/RNA SynthesisRisdiplam
Chemical structure of CAS 1825352-65-5

Risdiplam

In Stock•Starting at $154 for 50 mg•Purity ≥ 99%
CAS No.1825352-65-5
MDL No.MFCD31657372
MFC22H23N7O
MW401.50
InChI KeyASKZRYGFUPSJPN-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg99%$154In Stock
100 mg99%$260In Stock
250 mg99%$438In Stock
1 g99%$1181In Stock
5 g99%$3063In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1825352-65-5
Product NameRisdiplam

Biological Targets

SMN2

Associated Conditions

spinal muscular atrophy·Atrophy·proximal spinal muscular atrophy
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Reproductive findings in male animals exposed to selective survival of motor neuron 2 (SMN2) gene splicing-modifying agents.

Reproductive toxicology (Elmsford, N.Y.) • Vol. 118 • 2023
PMID: 36894038DOI: 10.1016/j.reprotox.2023.108360

The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.

Neuromuscular disorders : NMD • Vol. 29, Issue 1 • 2019
PMID: 30553700DOI: 10.1016/j.nmd.2018.10.001

Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs.

Pharmacology research & perspectives • Vol. 6, Issue 6 • 2018
PMID: 30519476PMC: PMC6262736DOI: 10.1002/prp2.447

Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA).

Journal of medicinal chemistry • Vol. 61, Issue 15 • 2018
PMID: 30044619DOI: 10.1021/acs.jmedchem.8b00741

Documentation

Similar Products